Background: We examined the hypothesis that mixed-dilution online hemodiafiltration (MIXED) rather than predilution online hemodiafiltration (PRE) could enable patients with low blood flow rate (Qb) to benefit from advantages of convective therapies. Methods: Thirty-eight patients were included in a prospective, randomized, crossover and multicenter study conducted with a view to comparing the equilibrated Kt/V, reduction ratio (RR) of phosphates, β2-microglobulin (β2-M) and myoglobin (myo) between PRE and MIXED, each at two Qb values of 250 and 300 ml/min during 4 h sessions with a FX1000HDF dialyzer. Albumin losses (Alb) were also measured in 12 patients. Results: MIXED was always found to be more efficient compared to PRE notably for middle molecules (MM). RRβ2-M: MIX250: 81.3 ± 3.6 vs. PRE250: 75.2 ± 5.9; MIX300: 82.7 ± 3.6 vs. PRE300: 78.1 ± 5.4; RRmyo: MIX250: 70.2 ± 3.6 vs. PRE250: 42.6 ± 2.6; MIX300: 70.6 ± 3.6 vs. PRE300: 45.7 ± 3.6 and with Alb <3.0 g/session. Conclusion: MIXED allows patients unable to provide sufficiently high Qb to achieve high levels of MM removal.

Keywords:
Albumin loss, Blood flow rates, Middle molecule removal , Mixed-dilution online hemodiafiltration, Online hemodiafiltration, Predilution online hemodiafiltration
1.
Canaud B, Bragg-Gresham JL, Marshall MR, et al: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-2093.
2.
Masakane I: Selection of dilutional method for on-line HDF, pre- or post-dilution. Blood Purif 2004;22(suppl 2):49-54
3.
Wizeman V, Külz M, Rechert F, et al: Efficacy of haemodiafiltration. Nephrol Dial Transplant 2001;16(suppl 4):27-30.
4.
Mandolfo S, Borlandelli S, Imbasciati E, et al: Pilot study to assess increased dialysis efficiency in patients with limited blood flow rates due to vascular access problems. Hemodial Int 2008;12:55-61.
5.
Krieter DH, Canaud B: High permeability of dialysis membranes: what is the limit of albumin loss? Nephrol Dial Transplant 2003;18:651-654.
6.
Bergström J, Wehle B: No change in corrected β2-microglobulin concentration after cuprophane hemodialysis. Lancet 1987;1:628-629.
7.
Feliciani A, Riva MA, Zerbi S, et al: New strategies in haemodiafiltration (HDF): prospective comparative analysis between on-line mixed HDF and mid-dilution HDF. Nephrol Dial Transplant 2007;22:1672-1679.
8.
Krieter DH, Falkenhain S, Chalabi L, et al: Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration. Kidney Int 2005;67:349-356.
9.
Maduell F, Arias M, Vera M, et al: Mid-dilution hemodiafiltration: a comparison with pre- and postdilution modes using the same polyphenylene membrane. Blood Purif 2009;28:268-274.
10.
Potier J: Mid-dilution: an innovative high-quality and safe haemodiafiltration approach. Contrib Nephrol. Basel, Karger, 2007, vol 158, pp 153-160.
11.
Maduell F, Arias M, Fontsere N, et al: What infusion flow should be used for mid- dilution hemodiafiltration? Blood Purif 2010;30:25-33.
12.
Pedrini LA, De Cristofaro V: On-line mixed hemodiafiltration with a feedback for ultrafiltration control: effect on middle-molecule removal. Kidney Int 2003;64:1505-1513.
13.
Pedrini LA, De Cristofaro V, Pagliari B, et al: Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes. Kidney Int 2000;58:2155-2165.
14.
Pedrini LA, Cozzi G, Faranna P, et al: Transmembrane pressure modulation in high-volume mixed hemodiafiltration to optimize efficiency and minimize protein loss. Kidney Int 2006;69:573-579.
15.
Ward RA, Greene T, Hartmann B, et al: Resistance to intercompartmental mass transfer limits β2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006;69:1431-1437.
16.
Casino FG, Pedrini LA, Santoro A, et al: A simple approach for assessing equilibrated Kt/V β2M on a routine basis. Nephrol Dial Transplant 2010;25:3038-3044.
17.
Tentori F, Blayney MJ, Albert JM, et al: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-530.
18.
Lornoy W, Becaus I, Billiouw JM, et al: On-line haemodiafiltration. Remarkable removal of β2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 2000;15:49-54.
19.
Cheung AK, Rocco MV, Yan G, et al: Serum β2-microglobulinb levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006;17:546-555.
20.
Kim S: Characteristics of protein removal in hemodiafiltration. Contrib Nephrol. Basel, Karger, 1994, vol 108, pp 23-37.
21.
Vanholder R, Laecke SV, Glorieux G: The middle-molecule hypothesis 30 years after: lost and rediscovered in the universe of uremic toxicity? J Nephrol 2008;21:146-160.
22.
Ahrenholz P, Winkler RE, Mechelsen A, et al: Dialysis membrane-dependent removal of middle molecule during hemodiafiltration; the β2-microglobulin/albumin relationship. Clin Nephrol 2004;62:21-28.
23.
Lin CL, Yang CW, Chiang CC, et al: Long-term on-line hemodiafiltration reduces predialysis β2-microglobulin levels in chronic hemodialysis patients. Blood Purif 2001;19:301-307.
24.
Yeun JY, Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 1998;32(suppl 4):S118-S125.
25.
Cooper BA, Penne EL, Bartlett LH, et al: Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 2004;43:61-66.
26.
Kaysen GA: Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998;9:2368-2376.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.